Vaccitech Overview

  • Founded
  • 2016

Founded
  • Status
  • Public

  • Employees
  • 72

Employees
  • Stock Symbol
  • VACC

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $5.40

  • (As of Thursday Closing)

Vaccitech General Information

Description

Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Its therapeutic programs include VTP-300, VTP-200, VTP-850, and VTP-600. Its current prophylactic programs include VTP-400. In addition, it also co-invented a COVID-19 vaccine candidate with the University of Oxford known as COVID-19 Vaccine AstraZeneca.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • The Schrodinger Building, Heatley Road
  • The Oxford Science Park
  • Oxford OX4 4GE
  • England, United Kingdom
+44 01865 000000

Vaccitech Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaccitech Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.40 $6.21 $2.97 - $17.99 $201M 37.2M 18.4K -$1.08

Vaccitech Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (13,002) 162,293
Revenue 15,072 268 4,821 6,845
EBITDA (32,493) (47,872) (14,030)
Net Income (33,001) (50,865) (17,706)
Total Assets 286,123 280,715 50,666 19,043
Total Debt 6,735 7,222 46,364 1,778
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vaccitech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vaccitech‘s full profile, request access.

Request a free trial

Vaccitech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Vaccitech‘s full profile, request access.

Request a free trial

Vaccitech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunother
Drug Discovery
Oxford, United Kingdom
72 As of 2021
00000
0000 0000-00-00
00000000 00000

000000

inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis
0000000000000
Plymouth Meeting, PA
000 As of 0000
000.00
00000000 000.00

000000

boris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vaccitech Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 Venture Capital-Backed San Carlos, CA 00 00000 000000000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 63 competitors. Get the full list »

Vaccitech Patents

Vaccitech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11191825-B2 Compositions and methods for vaccination against influenza Active 16-Sep-2016 0000000000 0
US-20190307877-A1 Compositions and methods for vaccination against influenza Granted 16-Sep-2016 000000000

Vaccitech Executive Team (8)

Name Title Board Seat Contact Info
William Enright Chief Executive Officer & Board Member
Georgy Egorov Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Christopher Ellis Chief Operating Officer, Operations
Thomas Evans MD Chief Scientific Officer
Graham Griffiths Executive
You’re viewing 5 of 8 executive team members. Get the full list »

Vaccitech Board Members (12)

Name Representing Role Since
Alex Hammacher Oxford Science Enterprises Board Member 000 0000
Anne Phillips MD Vaccitech Board Member 000 0000
Joseph Scheeren Vaccitech Board Member 000 0000
Karen Dawes Vaccitech Board Member 000 0000
Pierre Morgon Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Vaccitech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vaccitech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vaccitech‘s full profile, request access.

Request a free trial

Vaccitech Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 10-Dec-2021 0000000000 Biotechnology 0000000 0
To view Vaccitech’s complete acquisitions history, request access »

Vaccitech Subsidiaries (1)

Company Name Industry Location Founded
000000 00000000000 Biotechnology Baltimore, MD 0000
To view Vaccitech’s complete subsidiaries history, request access »